hepatocellular carcinoma
Conditions
Interventions
Experimental group:Lenvatinib plus gefitinib
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. No history of allergy to lenvatinib, regorafenib, gefitinib or its components; 2. Aged > 18 years, and 35 g/L; 11. Blood routine: WBC > 2500, PLT > 600,000; 12. Coagulation function: PT prolongation < 2 s; 13. ECOG score < 2 points; 14. The pathological result is hepatocellular carcinoma (HCC); 15. Understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Patients who have previously used anti-tumor therapy other than lenvatinib; 3. Patients who received lenvatinib treatment and then received radiotherapy or radiofrequency ablation; 4. Patients who received more than one TACE treatment after receiving lenvatinib treatment; 5. Patients combined with other malignant tumors; 6. Patients with mental illness; 7. Patients who have participated in other clinical trials in the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor size;Alpha fetal protein;Protein Induced by Vitamin K Absence or Antagonist-II;overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;objective response rate;Adverse Event;Safety; | — |
Countries
China
Contacts
Public ContactLunxiu Qin
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed